OptimizeRx Corporation Confirms Receipt of Notice of Director Nominations

Core Points - OptimizeRx Corp. has received a notice from Whetstone Capital Advisors, LLC regarding the nomination of two candidates for the Board of Directors at the 2025 Annual Meeting of Stockholders [1] - The Board of Directors will provide a formal recommendation on the nominations in the definitive proxy statement to be filed with the SEC [2] Company Overview - OptimizeRx is a leading healthcare technology company that connects life science brands with patients and healthcare providers through innovative AI-driven tools [3] - The company focuses on patient-centric technology, ensuring meaningful interactions that deliver therapies to the right patients at the right time [4] Proxy Statement Information - OptimizeRx plans to file proxy materials with the SEC for the 2025 Annual Meeting, including a definitive proxy statement and a WHITE proxy card [6] - Stockholders are encouraged to read the proxy statement and related documents carefully when available, as they will contain important information [7] Participant Information - The company, its directors, and certain executive officers may be deemed "participants" in the proxy solicitation for the 2025 Annual Meeting [8]